Infantile hemangiomas, occurring at birth or during the first weeks of life, are benign vascular tumors with an initial proliferative phase and a later involutional phase. The massive proliferation on the key regions and unpredicted regression may threaten life. Thus, early management of infantile hemangiomas is necessary for affected infancies. Recent studies showed that propranolol for infantile hemangiomas had high efficacy for disappearance or reduction of infantile hemangiomas. However, a most recent study demonstrated existence of propranolol-resistant infantile hemangiomas. Therefore, we retrospectively evaluated efficacy of established early pulsed dye laser treatment for infantile hemangiomas in the 50 Japanese infancies which were applied in the period from 2000 to 2005, because our series included from the plaque subtype to the more proliferative tumor subtype. High efficacy in both subtypes suggests that early pulsed dye laser treatment can still be included as the first option for the mixed type of infantile hemangiomas and that pulsed dye laser treatment may be useful as the second line for the propranolol-resistant mixed type of infantile hemangiomas.
 N. Oiso, M. Kimura, S. Kawara and A. Kawada, “Clinical, Dermoscopic, and Histopathologic Features in a Case of Infantile Hemangioma without Proliferation,” Pediatric Dermatology, Vol. 28, No. 1, 2011, pp. 66-68. doi:10.1111/j.1525-1470.2010.01363.x
 M. Miyake, N. Oiso and A. Kawada. “Dermoscopic Appearances in the Superficial and Deep Type of Infantile Hemangioma,” Journal of Cosmetics, Dermatological Sciences and Applications, Vol. 2012, No. 2, 2012, pp. 212-213. doi:10.4236/jcdsa.2012.23038
 K. G. Chiller, D. Passaro and I. J. Frieden, “Hemangiomas of Infancy: Clinical Characteristics, Morphologic Subtypes, and Their Relationship to Race, Ethnicity, and Sex,” Archive of Dermatology, Vol. 138, No. 12, 2002, pp. 1567-1576. doi:10.1001/archderm.138.12.1567
 F. Corella, X. Garcia-Navarro, A. Ribe, A. Alomar and E. Baselga, “Abortive or Minimal-Growth Hemangiomas: Immunohistochemical Evidence That They Represent True Infantile Hemangiomas,” Journal of American Academy of Dermatology, Vol. 58, No. 4, 2008, pp. 685-690. doi:10.1016/j.jaad. 2007.08.007
 A. N. Haggstrom, B. A. Drolet, E. Baselga, S. L. Chamlin, M. C. Garzon, K. A. Horii, A. W. Lucky, A. J. Mancini, D. W. Metry, B. Newell, A. J. Nopper and I. Frieden, “Prospective Study of Infantile Hemangiomas: Clinical Characteristics Predicting Complications and Treatment,” Pediatrics, Vol. 118, No. 3, 2006, pp. 882-887. doi:10.1542/peds.2006-0413
 L. Zhang, H. M. Mai, J. Zheng, J. W. Zheng, Z. G. Chen, Y. A. Wang, Z. P. Qin, K. L. Li and W. E. Yuan, “Preliminary Study on Plasma RPN Concentration of Patients with Infantile Hemangioma Treated with Propranolol,” International Journal of Clinical and Experimental Medicine, Vol. 6, No. 5, 2013, pp. 342-345.
 S. Admani, A. C. Krakowski, J. S. Nelson, L. F. Eichenfield and S. F. Friedlander, “Beneficial Effects of Early Pulsed Dye Laser Therapy in Individuals with Infantile Hemangiomas,” Dermatologic Surgery, Vol. 38, No. 10, 2012, pp. 1732-1738. doi:10.1111/j.1524-4725.2012.02487.x
 Y. K. Tay and S. K. Tan, “Treatment of Infantile Hemangiomas with the 595-nm Pulsed Dye Laser Using Different Pulse Widths in an Asian Population,” Lasers in Surgery and Medicine, Vol. 44, No. 2, 2012, pp. 93-96. doi:10.1002/lsm.21159
 C. Léauté-Labrèze, E. D. de la Roque, T. Hubiche, F. Boralevi, J. B. Thambo and A. Ta?eb, “Propranolol for Severe Hemangiomas of Infancy,” The New England Journal of Medicine, Vol. 358, No. 24, 2008, pp. 2549-2651. doi:10.1056/NEJMc0708819
 V. Mendiratta, B. Varghese, R. Chander, A. Parakh and R. S. Solanki, “Successful Management of Airway Hemangioma with Propranolol,” International Journal of Dermatology, Vol. 52, No. 6, 2013, pp. 750-752. doi:10.1111/j.1365-4632.2012.05752.x
 B. A. Drolet, P. C. Frommelt, S. L. Chamlin, A. Haggstrom, N. M. Bauman, Y. E. Chiu, R. H. Chun, M. C. Garzon, K. E. Holland, L. Liberman, S. MacLellan-Tobert, A. J. Mancini, D. Metry, K. B. Puttgen, M. Seefeldt, R. Sidbury, K. M. Ward, F. Blei, E. Baselga, L. Cassidy, D. H. Darrow, S. Joachim, E. K. Kwon, K. Martin, J. Perkins, D. H. Siegel, R. J. Boucek and I. J. Frieden, “Initiation and Use of Propranolol for Infantile Hemangioma: Report of a Consensus Conference,” Pediatrics, Vol. 131, No. 1, 2013, pp. 128-140. doi:10.1542/peds.2012-1691
 S. Caussé, H. Aubert, M. Saint-Jean, E. Puzenat, A. C. Bursztejn, C. Eschard, E. Mahé, A. Maruani, J. Mazereeuw-Hautier, I. Dreyfus, J. Miquel, C. Chiaverini, O. Boccara, S. Hadj-Rabia, J. F. Stalder, S. Barbarot; The Groupe de Recherche Clinique en Dermatologie Pédiatrique, “Propranolol-Resistant Infantile Hemangiomas,” British Journal of Dermatology, Vol. 169, No. 1, 2013, pp. 125-129.
 S. Sommer S, D. C. Seukeran and R. A. Sheehan-Dare, “Efficacy of Pulsed Dye Laser Treatment of Port Wine Stain Malformations of the Lower Limb,” British Journal of Dermatology, Vol. 149, No. 4, 2003, pp. 770-775. doi:10.1046/j.1365-2133.2003.05467.x
 S. W. Lanigen and S. M. Taibjee, “Recent Advances in Laser Treatment of Port-Wine Stains,” British Journal of Dermatology, Vol. 151, No. 3, 2004, pp. 527-533. doi:10.1111/j.1365-2133.2004.06163.x
 R. R. Anderson and J. A. Parrish, “Selective Photothemolysis: Precise Microsurgery by Selective Absorption of Pulsed Radiation,” Science, Vol. 220, No. 4596, 1983, pp. 524-527. doi:10.1126/ science. 6836297